Dr. Harish Ahuja, Oncologist and ...

Dr. Harish G. Ahuja

Claim this profile

Langlade Hospital and Cancer Center

Studies Lung Cancer
Studies Breast Cancer
37 reported clinical trials
86 drugs studied

About Harish G. Ahuja

Education:

  • Obtained a Medical degree (MD) from the University of Wisconsin School of Medicine and Public Health.
  • Completed Residency in Radiation Oncology at the University of Wisconsin Hospital and Clinics.
  • Undertook a Fellowship in Stereotactic Radiosurgery and Brachytherapy at the same institution.

Experience:

  • Currently serves as a Radiation Oncologist at Aspirus Regional Cancer Center.

Area of expertise

1Lung Cancer
Harish G. Ahuja has run 10 trials for Lung Cancer. Some of their research focus areas include:
Stage III
Stage II
Stage IV
2Breast Cancer
Harish G. Ahuja has run 8 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
ER negative

Affiliated Hospitals

Image of trial facility.
Langlade Hospital And Cancer Center
Image of trial facility.
Aspirus Regional Cancer Center

Clinical Trials Harish G. Ahuja is currently running

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Nivolumab + Ipilimumab + Sargramostim

for Advanced Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria

More about Harish G. Ahuja

Clinical Trial Related6 years of experience running clinical trials · Led 37 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Harish G. Ahuja has experience with
  • Atezolizumab
  • Carboplatin
  • Fluorouracil
  • Paclitaxel
  • Pembrolizumab
  • Cisplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Harish G. Ahuja specialize in?
Is Harish G. Ahuja currently recruiting for clinical trials?
Are there any treatments that Harish G. Ahuja has studied deeply?
What is the best way to schedule an appointment with Harish G. Ahuja?
What is the office address of Harish G. Ahuja?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security